TABLE 3.
The incidence of adverse reactions in the three groups of patients, with a p-value indicating a statistically significant difference between the Nefecon group and the Glucocorticoids group.
| Adverse reactions, n% | Support group (n = 67) | Glucocorticoids group (n = 42) | Nefecon group (n = 40) | P value |
|---|---|---|---|---|
| Infection | 2 (3.0) | 4 (9.5) | 2 (5.0) | |
| Simple increase in white blood cells | | 3 (7.1) | 10 (25.0) | |
| High blood sugar | 1 (1.5) | 3 (7.1) | 4 (10.0) | |
| Anemia | 1 (1.5) | 4 (9.5) | 3 (7.5) | |
| Menstrual disorders | | | 1 (2.5) | |
| Obesity | | 2 (4.8) | | |
| Edema | | 1 (2.4) | | |
| Dizziness | | 1 (2.4) | | |
| Incidence of AEs | 4 (6.7%) | 18 (42.9%) | 20 (50%) | 0.52 |